In a clinical experiment of anti-GPC3 monoclonal antibody for HCC patients, Zhu et al. [17] reported that the effectiveness of this treatment was limited by GPC3 expression on the surface of HCC cells, that is, the therapy showed a significant effect when GPC3 was at high levels. The gene discussed is GPC3; the disease is hepatocellular carcinoma.